A Phase 4 interventional study of Brimonidine 0.33% gel (Br) and CD07805/47 (Br) placebo gel in Rosacea, sponsored by Galderma R&D. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.
Among the 11 studies testing brimonidine in Rosacea, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 4 in phase 4, and was the 9th registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →
brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2015.
This study's enrollment of 190 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 205 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 4 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
28 studies in Rosacea by Galderma Group AG: none open now, none under way, none of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 28 studies in Rosacea by Galderma Group AG, this one is the 13th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2015, is one of 9 in phase 4, and was the 26th registered.
Galderma Group AG’s Rosacea studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing brimonidine in Rosacea, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 28 in Rosacea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Half group will receive once-daily Br 0.33% gel in the morning and once-daily IVM 1% cream in the evening for 12 weeks. Half group will receive once-daily Br vehicle gel in the morning for the first 4 weeks and once-daily Br 0.33% gel in the morning for the following 8 weeks and once-daily IVM 1% cream in the evening for 12 weeks.
Drug: Brimonidine 0.33% gel (Br) · Other: CD07805/47 (Br) placebo gel · Drug: Ivermectin 1% cream (IVM)
Subjects will receive once-daily Br vehicle gel in the morning and once-daily IVM vehicle cream in the evening for 12 weeks.
Other: CD07805/47 (Br) placebo gel · Other: CD5024 (IVM) placebo cream
Efficacy Variable: Percentage of Patients Defined as Success on the Global Rosacea Severity Grading Scale Called Investigator's Global Assessment (IGA):
Percentage of patients defined as success as per scores of IGA; ie: clear (score=0) or almost clear (score=1)
Time frame: week 12/Hour 3
| Milestone | Brimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% Cream | CD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo Cream |
|---|---|---|
| Started | 95 | 95 |
| Completed | 85 | 86 |
| Not completed | 10 | 9 |
Percentage of patients defined as success as per scores of IGA; ie: clear (score=0) or almost clear (score=1)
| Participants | Brimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% Cream | CD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo Cream |
|---|---|---|
| Efficacy Variable: Percentage of Patients Defined as Success on the Global Rosacea Severity Grading Scale Called Investigator's Global Assessment (IGA): | 53 | 35 |
Collected over All AEs occurring after subject's consent and during the study were recorded; 3 months for a given subject 10 months for the study; ie: from first subject enrolled until last visit of last subject enrolled. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% Cream | 0/95 (0%) | 5/95 (5.3%) | 8/95 (8.4%) |
| CD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo Cream | 0/95 (0%) | 1/95 (1.1%) | 13/95 (13.7%) |
| Event | Brimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% Cream | CD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo Cream |
|---|---|---|
| atrial fibrillationCardiac disorders | 1/95 | 0/95 |
| Biliary cirrhosis primaryHepatobiliary disorders | 1/95 | 0/95 |
| PneumoniaInfections and infestations | 0/95 | 1/95 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 1/95 | 0/95 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/95 | 0/95 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/95 | 0/95 |
| Event | Brimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% Cream | CD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo Cream |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/95 | 5/95 |
| nasopharyngitisInfections and infestations | 3/95 | 5/95 |
| erythemaSkin and subcutaneous tissue disorders | 3/95 | 1/95 |
| rosaceaSkin and subcutaneous tissue disorders | 0/95 | 2/95 |
| Age, Continuous(years) | Brimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% Cream | CD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo Cream | Total |
|---|---|---|---|
| Mean | 51.0 ± 14.8 | 48.0 ± 13.6 | 50.0 ± 14.2 |
| Sex: Female, Male(Participants) | Brimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% Cream | CD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo Cream | Total |
|---|---|---|---|
| Female | 28 | 25 | 53 |
| Male | 67 | 70 | 137 |
The record gives a start of Dec 2015, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brimonidine · Ivermectin